X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12079) 12079
Book Chapter (37) 37
Dissertation (6) 6
Publication (5) 5
Magazine Article (4) 4
Book / eBook (2) 2
Web Resource (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7029) 7029
animals (6026) 6026
glucagon-like peptide-1 (5981) 5981
male (5017) 5017
endocrinology & metabolism (4705) 4705
glucagon (2994) 2994
female (2974) 2974
glucose (2974) 2974
diabetes (2831) 2831
glucagon-like peptide 1 (2792) 2792
insulin (2718) 2718
type 2 diabetes (2456) 2456
rats (2313) 2313
diabetes mellitus, type 2 - drug therapy (2222) 2222
mice (2212) 2212
glp-1 (2176) 2176
peptides (1945) 1945
blood glucose - metabolism (1916) 1916
middle aged (1856) 1856
obesity (1855) 1855
glucagon-like peptide 1 - metabolism (1843) 1843
adult (1793) 1793
insulin - metabolism (1750) 1750
hypoglycemic agents - therapeutic use (1548) 1548
secretion (1454) 1454
insulin - blood (1385) 1385
diabetes mellitus (1334) 1334
insulin secretion (1324) 1324
glucagon-like peptide-1 receptor (1254) 1254
pharmacology & pharmacy (1249) 1249
physiological aspects (1210) 1210
glucagon-like peptide 1 - blood (1195) 1195
research (1177) 1177
dextrose (1164) 1164
liraglutide (1160) 1160
physiology (1130) 1130
metabolism (1129) 1129
insulin resistance (1115) 1115
diabetes mellitus, type 2 - metabolism (1091) 1091
analysis (1073) 1073
aged (1011) 1011
diabetes mellitus, type 2 - blood (988) 988
food-intake (984) 984
glycemic control (979) 979
biochemistry & molecular biology (955) 955
hypoglycemic agents - pharmacology (950) 950
digestive, oral, and skin physiology (946) 946
glucose metabolism (915) 915
expression (906) 906
peptides - pharmacology (906) 906
exenatide (898) 898
health aspects (856) 856
nutrition & dietetics (854) 854
glucagon-like peptide 1 - analogs & derivatives (841) 841
rodents (840) 840
medicine & public health (834) 834
endocrine system (824) 824
glucagon-like peptide 1 - pharmacology (817) 817
abridged index medicus (815) 815
blood glucose - drug effects (800) 800
glucose - metabolism (798) 798
treatment outcome (796) 796
insulin-secretion (787) 787
internal medicine (786) 786
mice, inbred c57bl (783) 783
care and treatment (764) 764
body weight (756) 756
hyperglycemia (754) 754
hormones (745) 745
gastric-inhibitory polypeptide (738) 738
beta-cell function (737) 737
peptide fragments - pharmacology (727) 727
receptor (722) 722
incretin (718) 718
glucose tolerance test (715) 715
rats, sprague-dawley (704) 704
glucagon - metabolism (703) 703
hormones, hormone substitutes, and hormone antagonists (703) 703
insulin-secreting cells - metabolism (670) 670
glucagon-like peptide 1 - therapeutic use (668) 668
homeostasis (654) 654
exendin-4 (651) 651
receptors, glucagon - metabolism (647) 647
risk factors (646) 646
rats, wistar (636) 636
insulin-resistance (635) 635
hypoglycemic agents - administration & dosage (632) 632
surgery (623) 623
type-2 diabetes-mellitus (615) 615
glucagon-like peptides (610) 610
metformin (610) 610
hypoglycemic agents (603) 603
venoms - pharmacology (592) 592
proteins (584) 584
signal transduction (583) 583
glucagon - blood (577) 577
time factors (571) 571
appetite (569) 569
pancreas (568) 568
bariatric surgery (566) 566
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11906) 11906
Japanese (92) 92
Chinese (50) 50
German (48) 48
Spanish (24) 24
French (20) 20
Korean (19) 19
Hungarian (13) 13
Russian (12) 12
Polish (8) 8
Czech (7) 7
Danish (7) 7
Dutch (4) 4
Italian (4) 4
Portuguese (4) 4
Swedish (4) 4
Finnish (2) 2
Hebrew (1) 1
Norwegian (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Atherosclerosis, ISSN 0021-9150, 2012, Volume 221, Issue 2, pp. 375 - 382
.... ► In summary, liraglutide can reduce oxidative stress and inflammation in HUVEC. Glucagon-like peptide 1 (GLP-1... 
Cardiovascular | Oxidative stress | NF-κB | Endothelial cell | Inflammation | Apoptosis | CHRONIC HEART-FAILURE | TRANSLOCATION | PROTEIN-KINASE-C | PENTRAXIN 3 | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | IN-VITRO | NF-kappa B | ACUTE MYOCARDIAL-INFARCTION | DEGRADATION | PERIPHERAL VASCULAR DISEASE | DYSFUNCTION | VASCULAR NAD(P)H OXIDASE | Tumor Necrosis Factor-alpha - metabolism | Phosphorylation | Reactive Oxygen Species - metabolism | Human Umbilical Vein Endothelial Cells - metabolism | Membrane Glycoproteins - metabolism | Protein Kinase C-alpha - metabolism | Apoptosis - drug effects | Humans | NADPH Oxidases - metabolism | Human Umbilical Vein Endothelial Cells - immunology | NF-kappa B - metabolism | I-kappa B Proteins - metabolism | Dose-Response Relationship, Drug | C-Reactive Protein - metabolism | Transfection | I-kappa B Kinase - metabolism | Time Factors | Inflammation Mediators - metabolism | Superoxide Dismutase - metabolism | Recombinant Proteins - metabolism | Glutathione Peroxidase - metabolism | Human Umbilical Vein Endothelial Cells - drug effects | Anti-Inflammatory Agents - pharmacology | Glucagon-Like Peptide 1 - analogs & derivatives | Cells, Cultured | Glucagon-Like Peptide 1 - pharmacology | Antioxidants - pharmacology | NADPH Oxidase 2 | Protein Transport | Catalase - metabolism | NF-kappa B - genetics | Signal Transduction - drug effects | Serum Amyloid P-Component - metabolism | Oxidative Stress - drug effects | Liraglutide
Journal Article
Diabetes, ISSN 0012-1797, 04/2012, Volume 61, Issue 4, pp. 888 - 896
Journal Article
Obesity research, ISSN 1071-7323, 2005, Volume 13, Issue 6, pp. 1000 - 1007
.... On day 50, rats were food‐deprived 8 hours and anesthetized for blood and intestinal tissue sampling for further proglucagon mRNA, glucagon‐like peptide (GLP)‐1, and GLP‐2 quantification. Results... 
fructans | ghrelin | anorexigenic | gut peptides | orexigenic | LIPID-METABOLISM | GLP-1 | CARBOHYDRATE | ENERGY-INTAKE | INSULIN | ZUCKER RATS | NUTRITION & DIETETICS | ENDOCRINOLOGY & METABOLISM | SECRETION | OBESE | Dietary Fats - metabolism | Peptides - blood | Dipeptidyl Peptidase 4 - metabolism | Glucagon-Like Peptide 1 | Glucagon-Like Peptide 2 | Obesity - drug therapy | Protein Precursors - blood | Rats, Wistar | Glucagon - genetics | Intestinal Mucosa - secretion | Peptide Hormones - blood | Protein Precursors - secretion | Male | Intestines - metabolism | Glucagon - blood | Obesity - blood | Eating - physiology | Oligosaccharides - pharmacology | Peptide Hormones - metabolism | RNA, Messenger - biosynthesis | Peptides - metabolism | Ghrelin | Dietary Fats - administration & dosage | Peptide Fragments - blood | Peptides - secretion | Peptide Fragments - genetics | Proglucagon | Peptide Fragments - metabolism | Protein Precursors - genetics | Liver - metabolism | RNA, Messenger - genetics | Peptide Fragments - secretion | Rats | Oligosaccharides - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Obesity - metabolism | Protein Precursors - metabolism | Eating - drug effects | Animals | Triglycerides - blood | Glucagon - metabolism | Glucagon - secretion | Body Weight - physiology
Journal Article
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1524-4636, 2010, Volume 30, Issue 7, pp. 1407 - 1414
.... Here we investigated whether the antidiabetic hormone glucagon-like peptide 1 (GLP-1) could prevent oxidative stress-induced cellular senescence in endothelial cells... 
endothelium | APOPTOSIS | TRANSCRIPTION | glucagon-like peptide 1 | ATHEROSCLEROSIS | diabetes mellitus | ZUCKER RAT | NEPHROPATHY | UMCG Approved | senescence | reactive oxygen species | CARDIOVASCULAR-DISEASE | NITRIC-OXIDE | DYSFUNCTION | GLP-1 RECEPTOR | DIABETIC FATTY RATS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Diabetes Mellitus - enzymology | Diabetes Mellitus - pathology | Heme Oxygenase-1 - metabolism | Oxidants - pharmacology | Reactive Oxygen Species - metabolism | Nitriles - pharmacology | Humans | Cellular Senescence - drug effects | Male | Phosphatidylinositol 3-Kinases - metabolism | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - pharmacology | Dose-Response Relationship, Drug | Proto-Oncogene Proteins c-akt - metabolism | Cyclic AMP - metabolism | Adamantane - analogs & derivatives | Disease Models, Animal | Cyclic AMP-Dependent Protein Kinases - metabolism | Adamantane - pharmacology | Glucagon-Like Peptide 1 - metabolism | Signal Transduction | Cells, Cultured | Diabetes Mellitus - drug therapy | Hydrogen Peroxide - pharmacology | Rats | Receptors, Glucagon - metabolism | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Rats, Zucker | Animals | Glucagon-Like Peptide-1 Receptor | Cyclic AMP Response Element-Binding Protein - metabolism | NAD(P)H Dehydrogenase (Quinone) - metabolism | Venoms - pharmacology | DNA Damage | Enzyme Activation | Oxidative Stress - drug effects | Endothelial Cells - pathology | Endothelial Cells - enzymology | Endothelial Cells - drug effects
Journal Article
The Journal of clinical investigation, ISSN 1558-8238, 2017, Volume 127, Issue 10, pp. 3835 - 3844
Journal Article
Journal Article
Diabetes (New York, N.Y.), ISSN 1939-327X, 2018, Volume 67, Issue 8, pp. 1538 - 1548
Glucagon-like peptide 1 receptor (GLP-1R) agonists are U.S. Food and Drug Administration-approved weight loss drugs... 
GLUCOSE-HOMEOSTASIS | ENERGY-EXPENDITURE | VISCERAL ILLNESS | FOOD-INTAKE | NUCLEUS | ENDOCRINOLOGY & METABOLISM | GLP-1 RECEPTORS | MICE | BRAIN ACTIVATION | AREA POSTREMA | AGONIST | Neurons - pathology | Vesicular Glutamate Transport Protein 2 - chemistry | Obesity - drug therapy | Diet, High-Fat - adverse effects | Glucagon-Like Peptide-1 Receptor - chemistry | Male | Green Fluorescent Proteins - genetics | Nerve Net - drug effects | Weight Loss - drug effects | Appetite Depressants - therapeutic use | Recombinant Fusion Proteins - metabolism | Glucagon-Like Peptide-1 Receptor - genetics | Glucagon-Like Peptide-1 Receptor - metabolism | Nerve Tissue Proteins - chemistry | Obesity - etiology | Neurons - metabolism | GABAergic Neurons - metabolism | Hypothalamus - drug effects | Green Fluorescent Proteins - chemistry | Neurons - drug effects | Vesicular Glutamate Transport Protein 2 - genetics | Hypoglycemic Agents - therapeutic use | Green Fluorescent Proteins - metabolism | Nerve Tissue Proteins - agonists | Vesicular Glutamate Transport Protein 2 - metabolism | GABAergic Neurons - drug effects | Mice, Transgenic | Energy Intake - drug effects | Hypothalamus - pathology | Random Allocation | Recombinant Fusion Proteins - chemistry | Nerve Tissue Proteins - genetics | Mice, Knockout | Obesity - metabolism | Obesity - pathology | Nerve Tissue Proteins - metabolism | Animals | Hypothalamus - metabolism | Vesicular Inhibitory Amino Acid Transport Proteins - metabolism | Vesicular Inhibitory Amino Acid Transport Proteins - chemistry | Liraglutide - therapeutic use | Vesicular Inhibitory Amino Acid Transport Proteins - genetics | Nerve Net - metabolism | Genes, Reporter - drug effects | Glucagon-Like Peptide-1 Receptor - agonists | Appetite | Glucagon | Body weight | Dosage and administration | Research | Gene expression | Health aspects | Liraglutide | Index Medicus | Abridged Index Medicus | 0707 | Obesity Studies
Journal Article